Enlicitide decanoate

PCSK9 binds the hepatic LDL receptor and routes it to lysosomal degradation instead of letting it recycle to the cell surface. Enlicitide is a macrocyclic peptide engineered to occupy the PCSK9-LDLR interface with antibody-like affinity while remaining small and conformationally constrained enough to survive the gut and reach the portal circulation. The result is more LDL receptors on hepatocytes, faster LDL clearance, and reductions in non-HDL cholesterol, apolipoprotein B and lipoprotein(a) alongside LDL-C. The engineering achievement here matters as much as the drug: it is the first macrocyclic peptide to hit a protein-protein interaction target orally at scale, and the decanoate salt exists specifically to improve oral absorption.

Targets: PCSK9, Hepatic LDL receptor recycling, Apolipoprotein B

• · 20 mg once daily as an adjunct to diet and statin therapy. The fasting window is not optional - oral peptide absorption collapses with food. Placebo-adjusted LDL-C reduction was about 56 percent in primary hypercholesterolaemia and 59 percent in heterozygous familial hypercholesterolaemia at 24 weeks.

Work out your exact syringe units →

• very commonOverall adverse event profile comparable to placebo in phase 3— CORALreef Lipids reported safety broadly similar to placebo across 2,909 patients.
• commonGastrointestinal upset - nausea, diarrhoea— Expected with an oral peptide that requires a fasting window.
• commonMusculoskeletal pain— Difficult to separate from background statin therapy in the trials.
• rareHypersensitivity reaction

• Known hypersensitivity to enlicitide or its excipients.
• Pregnancy and breastfeeding, where lipid-lowering therapy is generally withheld and no data exist.
• Taking it with food, which is not a contraindication so much as a guarantee it will not work properly.

• synergystatins — The intended combination - statins raise PCSK9 levels, which enlicitide then blocks, giving additive LDL reduction.
• synergyezetimibe — Complementary mechanism; the CORALreef AddOn trial studied exactly this comparison.
• redundantevolocumab — Same target. There is no reason to take an oral and an injectable PCSK9 inhibitor together.
• conflictfood and non-water beverages — Food within 30 minutes of dosing substantially impairs absorption of this oral peptide.

• · Fasting lipid panel at baseline and roughly 8-12 weeks after starting, then periodically.
• · Apolipoprotein B and lipoprotein(a) if those are treatment targets.
• · Adherence to the fasting window, which is the single most common reason for a blunted response.

FDA-approved prescription drug in the United States as of July 2026, marketed as Lipfendra. Regulatory review continues in other regions.

• Lipfendra (enlicitide) FDA prescribing information, approved July 2026 (label)
• CORALreef Lipids phase 3 trial of enlicitide in adults with or at risk for ASCVD (NCT05952856) (trial)
• CORALreef Outcomes cardiovascular outcomes trial (NCT06008756), ongoing (trial)

PCSK9 is a secreted protein that binds the EGF-A domain of the LDL receptor at the hepatocyte surface. Normally, when an LDL receptor internalises its cargo, the acidic endosome releases the LDL particle and the receptor recycles back to the surface, roughly 150 times over its lifetime. PCSK9 binding changes that: the receptor-PCSK9 complex is routed to the lysosome and degraded instead of recycled. Fewer receptors on the surface means less LDL clearance and a higher plasma LDL cholesterol. Every PCSK9 drug works by preventing that interaction, and the difference between them is molecular format. Monoclonal antibodies (evolocumab, alirocumab) mop up circulating PCSK9 and must be injected. Inclisiran is a siRNA that stops hepatocytes making PCSK9 in the first place and is injected twice a year. Enlicitide is a macrocyclic peptide small enough to be swallowed but shaped to occupy the same EGF-A binding interface on PCSK9 that the antibodies target, which is a genuinely difficult medicinal chemistry problem: peptides that big are normally digested, not absorbed. Solving it is why this compound matters. The pharmacological consequence is the same downstream biology as the injectables, and the numbers bear that out: roughly 57 to 58 percent LDL-C reduction at week 24, about 48 percent lower apolipoprotein B, about 52 percent lower non-HDL cholesterol, and around 25 percent lower lipoprotein(a). Those are antibody-class numbers from a tablet.

The realistic failure mode is not toxicity, since adverse event rates matched placebo across 2,909 patients over 52 weeks, but adherence and administration. A daily fasted tablet with strict timing requirements is easier to get wrong than a monthly injection, and the entire advantage of an oral PCSK9 inhibitor evaporates if patients take it with food. The evidence gap is the second issue: the LDL, ApoB and Lp(a) effects are excellent and replicated, but CORALreef Outcomes has not reported, so cardiovascular event reduction for this specific drug is an inference from the LDL hypothesis rather than a demonstrated result. That inference is a strong one given how consistently LDL lowering has translated into event reduction across drug classes, but it is still an inference.

• PCSK9 (EGF-A binding interface)

  Blocks PCSK9 from binding the LDL receptor's EGF-A domain, so the receptor recycles to the hepatocyte surface instead of being routed to the lysosome. Net effect is a large increase in hepatic LDL receptor density and a 55 to 60 percent fall in LDL cholesterol.

• LDL receptor (indirect)

  Not a direct target. Receptor density rises because degradation is prevented, which is also why the effect is additive on top of statins, which raise receptor transcription.

• CORALreef Lipids (NCT05952856) Phase 3 · n=2909 · 52 weeks · 2026

  Mean percent change in LDL cholesterol from baseline to week 24 in adults with or at risk of atherosclerotic cardiovascular disease, randomised 2:1 to enlicitide 20 mg daily or placebo. Result: -57.1 percent versus +3.0 percent, an adjusted between-group difference of -55.8 percentage points (p<0.001). Adverse events did not differ from placebo.

• CORALreef HeFH (NCT05952869) Phase 3 · n=303 · 52 weeks · 2026

  Mean percent change in LDL-C at week 24 in heterozygous familial hypercholesterolaemia on background statin: -58.2 percent versus +2.6 percent on placebo (between-group difference -59.4 percent). ApoB fell 48.2 percent and median Lp(a) fell 24.7 percent.

• MK-0616 phase 2b Phase 2b · n=381 · 8 weeks · 2023

  Percent change in LDL-C at week 8 across four doses. Dose-dependent reductions of 41.2 percent (6 mg), 55.7 percent (12 mg), 59.1 percent (18 mg) and 60.9 percent (30 mg) versus placebo, all p<0.001. This is the dose-finding study that selected 20 mg for phase 3.

• CORALreef Outcomes (NCT06008756) Phase 3 · n=14550

  Major adverse cardiovascular events. Active, not recruiting as of mid-2026. Until this reads out, hard-endpoint benefit for enlicitide is inferred from the LDL hypothesis rather than demonstrated for this drug.

LDL cholesterol falls quickly; the phase 2b programme measured its primary endpoint at 8 weeks and full effect was already present. Effect is maintained at 52 weeks (-55.3 percent in the familial hypercholesterolaemia trial). On stopping, LDL returns toward baseline over weeks as PCSK9 levels recover.

Enlicitide is designed to sit on top of a statin, and the trials were run that way: 81.5 percent of the familial hypercholesterolaemia cohort were on a high-intensity statin and 64 percent were also on ezetimibe, and the 58 percent LDL reduction was on top of all of that. The mechanisms are complementary rather than redundant, since statins raise LDL receptor transcription and also raise PCSK9, which partly blunts their own effect, and blocking PCSK9 removes that brake. Combining it with another PCSK9 agent, whether an antibody or inclisiran, is pointless. The interaction that matters most is not with another drug but with food: absorption depends on fasted dosing with a specified water volume, and a patient who takes it with breakfast is taking a much smaller dose than they think. A dedicated lithium interaction study was run, which suggests the permeation enhancer's effects on gut absorption of other drugs were a specific concern.

Against evolocumab and alirocumab: comparable LDL reduction, comparable ApoB and Lp(a) effects, and a tablet instead of a fortnightly or monthly injection, but those antibodies have completed cardiovascular outcomes trials (FOURIER and ODYSSEY OUTCOMES) and enlicitide has not. Against inclisiran: inclisiran is dosed twice a year after loading, which is unbeatable for adherence, but delivers a smaller LDL reduction of roughly 50 percent and also lacks a completed outcomes trial. Against bempedoic acid: not in the same league on LDL lowering. For a patient who cannot or will not inject, this is now the only way to get antibody-class LDL lowering.

Newly approved and I could not verify a launch price in this session. The commercial premise of an oral PCSK9 inhibitor is that it should undercut the injectable antibodies, but that is an expectation, not a verified number.

• ?Essentially the entire pharmacokinetic profile is unpublished in sources I could resolve: tmax, bioavailability, volume of distribution, clearance, protein binding, half-life and time to steady state are all null.
• ?The Core record states FDA approval on 16 July 2026 as Lipfendra; no DailyMed label was available at the time of writing, so I could not independently verify the approval or read the labelled dosing and monitoring language.
• ?The fasted-dosing requirement is inferred from the existence of dedicated food-effect and water-volume phase 1 studies on the trial registry, not read off a prescribing information document.
• ?Molecular weight and sequence are not stated in the Core record and I did not resolve them.

• A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide Navar AM, Mikhailova E, Catapano AL, et al. (CORALreef Lipids Investigators), N Engl J Med, 2026 · PMID 41879224

  The pivotal phase 3 trial, 2,909 patients, 57.1 percent LDL-C reduction at week 24.

• Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial Ballantyne CM, Gellis L, Tardif JC, et al., JAMA, 2026 · PMID 41206969

  The familial hypercholesterolaemia trial, including the apolipoprotein B and lipoprotein(a) numbers.

• Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616 Ballantyne CM, Banka P, Mendez G, et al., J Am Coll Cardiol, 2023 · PMID 36889610

  Dose-response across 6 to 30 mg; the flattening above 18 mg is why 20 mg was chosen.

• Total synthesis of enlicitide decanoate Li H, Yin J, et al., J Am Chem Soc, 2025 · PMID 40123407

  The chemistry, for anyone who wants to understand what an orally absorbed macrocyclic peptide actually looks like.

• MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment Burnett JR, Hooper AJ, Expert Opin Investig Drugs, 2023 · PMID 37815341

  Independent review of the development programme.